Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with complex immunological pathogenesis and diverse clinical features, as a consequence of multi-system inflammation (1). Although there has been a significant progress in the management of patients with SLE, there is an unmet need for specific diagnostic or predictive biomarkers for routine clinical use. Certain members of S100 protein family such as S100A8/9 and S100A12 are upregulated in several autoimmune inflammatory disorders, including SLE (2-4), and their potential as diagnostic or prognostic biomarkers is emerging. S100A11 (calgizzarin) is a less known S100 protein that has been extensively studied in cancer (5). Very recently, our group showed an implication of S100A11 in the pathogenesis of rheumatoid arthritis (RA) and thereby its potential role in autoimmune diseases (6). We described a local accumulation of S100A11 protein in the synovial tissues and fluids of patients with RA and its association with inflammation and disease activity (6). Altogether, these findings prompted our present study focusing on S100A11 in SLE.